BiotechTube

TD-9855 + TD-9855 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Attention-Deficit/Hyperactivity Disorder

Conditions

Attention-Deficit/Hyperactivity Disorder, ADHD

Trial Timeline

Dec 1, 2011 → Nov 1, 2013

NCT ID
NCT01458340

About TD-9855 + TD-9855 + Placebo

TD-9855 + TD-9855 + Placebo is a phase 2 stage product being developed by Theravance Biopharma for Attention-Deficit/Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01458340. Target conditions include Attention-Deficit/Hyperactivity Disorder, ADHD.

What happened to similar drugs?

8 of 11 similar drugs in Attention-Deficit/Hyperactivity Disorder were approved

Approved (8) Terminated (0) Active (3)
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
✅SPN-812Supernus PharmaceuticalsApproved
✅SPN-812Supernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01458340Phase 2Completed

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyApproved
43
ABT-089 + atomoxetine + placeboAbbViePhase 2
35
ABT-089 + PlaceboAbbViePhase 2
35
ABT-089AbbViePhase 2
35
ABT-089 + placeboAbbViePhase 2
35
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
43
SPN-812Supernus PharmaceuticalsApproved
37
IR Viloxazine + PlaceboSupernus PharmaceuticalsPhase 1/2
26
SPN-812Supernus PharmaceuticalsApproved
37
100mg SPN-812 + PlaceboSupernus PharmaceuticalsApproved
44
SPN-812Supernus PharmaceuticalsPhase 3
34
Placebo + SPN-812Supernus PharmaceuticalsPhase 3
34
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812Supernus PharmaceuticalsPhase 2
29
SPN-812Supernus PharmaceuticalsPhase 3
38